At its simplest, biotechnology is technology based on biology - biotechnology harnesses cellular and biomolecular processes to develop technologies and products that help improve our lives and the ...

As monoclonal antibody (mAb) programs approach IND, delays often stem from fragmented development, tech transfer complexity, and limited process efficiency. In this webinar, Thermo Fisher Scientific ...

At the 2026 BIO International Convention, we come together Driven by Purpose to forge meaningful connections and advance innovations that improve lives. Successful partnering starts with a clear ...

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry's economic ...

The Biotechnology Innovation Organization (BIO) is proud to announce that industry leader and military veteran John F. Crowley will be its new President and CEO, effective March 4. He will replace ...

WASHINGTON (March 26, 2025) -- Today, the Biotechnology Innovation Organization (BIO) released results from a membership survey that underscores the significant, global integration of the biomedical ...

Breaking: BIO has released the results of a survey revealing companies’ dependence on Chinese biomanufacturing. Yesterday, a busy day on Capitol Hill featured testimony from a BIO Board member and a ...

Washington, D.C. (May 25, 2016) – Today, the Biotechnology Innovation Organization (BIO) released the largest ever study of clinical development success rates. The study, conducted in partnership with ...

Today, the Biotechnology Innovation Organization (BIO) released a new report, "The State of Innovation in Vaccines and Prophylactic Antibodies for Infectious Diseases," examining the latest scientific ...

WASHINGTON D.C. – Today, the Biotechnology Innovation Organization (BIO), in partnership with Kearney, a global management consulting firm, released a first-of-its-kind report that assesses the ...

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on reports of the retirement of Richard Pazdur from the US FDA ...

Dear Colleagues, I am just past the two-year mark as BIO’s President & CEO, which arrives as we find ourselves at a defining moment for the future of biotechnology. For fifty years, our industry has ...